IP Verse

Zentiva Ks competitive analysis

Loading summary...

Explore patent oppositions filed by Zentiva Ks against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 23, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP3226841	Anticancer Compositions	ARAGON PHARMACEUTICALS	Jul 7, 2025
EP4321157	New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)	NOVARTIS	Jun 25, 2025
EP3090730	Novel Pharmaceutical Composition	NOVARTIS	Jan 10, 2025
EP2395968	Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A Patient	BOEHRINGER INGELHEIM	Oct 14, 2024
EP3494972	Combinations Of Dolutegravir And Lamivudine For The Treaetment Of Hiv Infection	VIIV HEALTHCARE	Sep 13, 2024
EP3626270	New Use	NOVARTIS	Jul 11, 2024
EP2981255	Therapeutic Uses Of Empagliflozin	BOEHRINGER INGELHEIM	Jun 13, 2023
EP2959894	S1P Receptor Modulators For Treating Multiple Sclerosis	NOVARTIS	Oct 12, 2022
EP2653873	Compositions And Uses For Treating Multiple Sclerosis	BIOGEN IDEC MA	Sep 23, 2022
EP3725778	Formulations Of Enzalutamide	ASTELLAS PHARMA	May 13, 2022

Explore the latest publications and patents granted to Zentiva Ks, showcasing their recent innovations and technological advancements.

Discover the latest PTAB cases involving Zentiva Ks, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Zentiva Ks with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
ZENTIVA KS	24	-	-	-
BRISTOL MYERS SQUIBB IRELAND	-	43	-	-
BRISTOL MYERS SQUIBB IRELAND UNLIMITED	-	43	-	-
NOVARTIS	6	422	-	21